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Introduction
Valosin-containing protein (VCP) is a ubiquitously expressed 
protein belonging to the AAA+ (ATPases associated with vari-
ous activities) protein family (Halawani and Latterich, 2006). 
VCP is implicated in multiple cellular processes, including cell 
cycle regulation, nuclear envelope formation, Golgi biogenesis, 
and the ubiquitin proteasome system (UPS; Halawani and 
Latterich, 2006). Of these functions, degradation of misfolded 
substrates synthesized through the secretory pathway is the best 
characterized (Ye et al., 2001). VCP in a complex with Ufd1 
and Npl4 participates in the retrotranslocation of ER-associated 
degradation (ERAD) substrates (Ye et al., 2001). Loss of VCP 
activity leads to the accumulation of ubiquitinated proteins and 
impaired ERAD (Dalal et al., 2004; Wójcik et al., 2004). VCP 
also facilitates protein aggregate trafficking to an inclusion 
body. The absence of VCP disrupts aggresome formation and 
the degradation of expanded polyglutamine-containing proteins 
(Kobayashi et al., 2007).
Consistent with VCP’s involvement in these processes, 
dominantly inherited mutations cause inclusion body myopathy 
(IBM), Paget’s disease of the bone (PDB), and frontotemporal 
dementia (FTD [IBMPFD]), which is a rare multisystem degen-
erative disorder with three variably penetrant phenotypic fea-
tures (Watts et al., 2004). 90% of patients develop disabling 
weakness by the fourth to fifth decade. At this same age, 51% 
of patients develop PDB. And 32% of patients develop FTD 
in the fifth to sixth decade. Other features in some families in-
clude cataracts, neuropathy, and cardiomyopathy, suggesting that 
IBMPFD pathogenesis may relate to other common age-associated 
diseases (Weihl et al., 2009).
Several shared pathological features exist in the disparate 
tissues affected in IBMPFD. Muscle and brain contain ubiquitin- 
and TDP-43 (TARDNA-binding protein 43)–positive inclusions 
(Schröder et al., 2005; Forman et al., 2006; Hübbers et al., 2007; 
Mutations in valosin-containing protein (VCP) cause inclusion body myopathy (IBM), Paget’s disease of the bone, and frontotemporal 
dementia (IBMPFD). Patient muscle has degenerating ﬁbers, 
rimmed vacuoles (RVs), and sarcoplasmic inclusions con-
taining ubiquitin and TDP-43 (TARDNA-binding protein 43). 
In this study, we ﬁnd that IBMPFD muscle also accumulates 
autophagosome-associated proteins, Map1-LC3 (LC3), 
and p62/sequestosome, which localize to RVs. To test 
whether VCP participates in autophagy, we silenced VCP 
or expressed adenosine triphosphatase–inactive VCP. 
Under basal conditions, loss of VCP activity results in 
autophagosome accumulation. After autophagic induc-
tion, these autophagosomes fail to mature into autolyso-
somes and degrade LC3. Similarly, IBMPFD mutant VCP 
expression in cells and animals leads to the accumulation 
of nondegradative autophagosomes that coalesce at RVs 
and fail to degrade aggregated proteins. Interestingly, 
TDP-43 accumulates in the cytosol upon autophagic inhi-
bition, similar to that seen after IBMPFD mutant expres-
sion. These data implicate VCP in autophagy and suggest 
that impaired autophagy explains the pathology seen in 
IBMPFD muscle, including TDP-43 accumulation.
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None of these previous findings explain all of the pathol-
ogy seen in IBMPFD patient muscle. Whether VCP is involved 
in autophagy is not known. In this study, we evaluate auto-
phagosome formation, maturation, and flux in cells and animals 
devoid of functional VCP or expressing IBMPFD mutant VCP. 
In addition, we assess the accumulation of cytosolic TDP-43 in 
IBMPFD mutant VCP–expressing cells and animals as well as 
under conditions of impaired autophagy.
Results
It is speculated that RVs are of autophagic origin. To see whether 
autophagic protein markers are elevated in IBMPFD muscle, we 
immunoblotted quadriceps muscle lysates from 9–12-mo-old 
control or VCP wild-type (WT)– or two different VCP-RH– 
expressing transgenic mouse lines (RH9 or RH12) using anti-
bodies to p62 or LC3. There was an increase in p62 (Fig. 1 A) 
and specifically the autophagosome-associated cleavage prod-
uct of LC3, LC3II, by approximately twofold in the RH9 and 
RH12 muscle (Fig. 1 B). The increase in p62 and LC3II levels 
is similar to that seen after the acute treatment of control mice 
with 50 mg/kg intraperitoneal hydroxychloroquine (chloro-
quine) per day for 48 h or chronic treatment for 4 wk (Fig. S1). 
Chloroquine is an inhibitor of autophagosome–lysosome fu-
sion, and treatment leads to a decrease in the degradation of 
autophagic substrates such as LC3II and p62. An immunoblot 
of muscle lysates from nine different IBMPFD patients muscle 
biopsies showed an approximately fivefold increase in p62 pro-
tein levels when compared with normal patient muscle (Fig. S2). 
As previously described, sIBM muscle had an increase in p62 
protein levels by approximately threefold (Nogalska et al., 
2009). Further characterization of IBMPFD mutant–expressing 
transgenic mice found that RH9 and RH12 muscle accumulated 
subsarcolemmal, diffuse, and punctate sarcoplasmic p62 and 
LC3 (Fig. 1, C and D). This pattern of p62 accumulation is simi-
lar to that seen after acute treatment of control mice with 50 
mg/kg intraperitoneal chloroquine per day for 48 h (Ju et al., 
2009) or chronic treatment for 4 wk (Fig. S5 D). In some in-
stances, p62 and LC3 localized to the center of a myofiber at a 
region consistent with an RV (Fig. 1 D). No similar pattern was 
seen in control or VCP-WT mouse muscle (Fig. 1 C). IBMPFD 
patient muscle had identical findings (Fig. S3). These data dem-
onstrate that the autophagosome markers p62 and LC3 are in-
creased in IBMPFD muscle and localize to RVs.
Because mutations in VCP lead to IBMPFD, we evaluated 
the effect of a loss of VCP on autophagy. After 4 d of VCP-
targeted siRNA oligonucleotide treatment (knockdown [KD]), 
VCP protein levels decreased by Y60–70% in U20S cells 
(Fig. 2 A). Immunoblots for p62 and LC3 using these same lysates 
demonstrated increased LC3II and p62 protein levels compared 
with scrambled control siRNA treatment (Scr; Fig. 2 A). Trans-
fection of similarly treated cells with a GFP-LC3 expression 
construct showed increased GFP-LC3 puncta under basal condi-
tions in VCP-KD cells compared with control Scr cells (Fig. 2 B). 
We further explored the effect of VCP on autophagy by using 
previously characterized tetracycline-inducible U20S cells that 
express myc-tagged VCP-WT, ATPase inactive VCP-E578Q 
Neumann et al., 2007; Weihl et al., 2008). In brain tissue, ubiq-
uitinated and TDP-43 inclusions are intranuclear, classifying 
IBMPFD as a frontotemporal lobar degeneration with ubiqui-
tinated inclusions (FTLD-U) subtype (Schröder et al., 2005; 
Forman et al., 2006). In muscle, ubiquitinated inclusions are 
myonuclear and sarcoplasmic (Guyant-Maréchal et al., 2006; 
Hübbers et al., 2007), and TDP-43 is diminished from the 
nuclei of inclusion-bearing myofibers (Weihl et al., 2008; 
Salajegheh et al., 2009). Why TDP-43 accumulates in the cyto-
sol of IBMPFD patients is unknown, but it is consistent with the 
behavior of TDP-43 in other FTLD-Us and sporadic amyo-
trophic lateral sclerosis (Neumann et al., 2006).
Another striking pathology in IBMPFD muscle is sarcoplas-
mic vacuoles (Watts et al., 2004). These vacuoles have characteris-
tics of rimmed vacuoles (RVs) found in other muscle degenerative 
disorders such as sporadic inclusion body myositis (sIBM) and he-
reditary IBM. The term RV is actually a misnomer because RVs are 
not lined by a limiting membrane and do not contain any specific 
cellular organelle contents. They are more appropriately described 
as an accumulation of membranous and proteinaceous debris 
within a myofiber. During tissue processing, this membranous 
accumulation is extracted, leaving an RV. Ultrastructural analysis 
demonstrates that RVs contain discontinuous membranous whorls 
admixed with tubulofilamentous and electron-dense material 
(Fernandez et al., 2005). The origin of RVs in sIBM and hereditary 
IBM is unclear but has been assumed to be autophagic.
How disease mutations in VCP affect its function is not 
fully understood. All described mutations reside within the 
N-terminal and D1 domains, which are regions proposed to be 
involved in substrate and cofactor association (Watts et al., 2004; 
Weihl et al., 2009). One initial study shows that IBMPFD mu-
tants still bind to Ufd1 and Npl4, which are essential for UPS 
function (Hübbers et al., 2007). Biochemical characterization 
of several disease mutations finds that they form stable hexa-
mers and have increased ATPase activity (Weihl et al., 2006; 
Halawani et al., 2009). The increased ATPase activity may re-
flect structural changes upon ATP binding (Halawani et al., 2009). 
Skeletal muscle–restricted expression of IBMPFD mutant VCP-
R155H (VCP-RH) in transgenic mice recapitulates many of the 
features seen in IBMPFD muscle, including weakness, myo-
pathic features, ubiquitinated inclusions, and vacuolation (Weihl 
et al., 2007). Expression of IBMPFD mutations in cell culture 
has shown mixed results. Some studies find an increase in ubiq-
uitinated proteins (Weihl et al., 2006; Ju et al., 2008), whereas 
others identify minimal or no change in its levels (Hübbers 
et al., 2007; Gitcho et al., 2009). How well cell culture can effec-
tively model IBMPFD may relate to cell type and protein ex-
pression level. ERAD and UPS substrates may also accumulate 
in IBMPFD mutant cells. The levels of the ERAD substrate 
$F508 cystic fibrosis transmembrane regulator (CFTR; Weihl 
et al., 2006) and UPS substrate Unc-45B (Janiesch et al., 2007) 
are increased in IBMPFD mutant cells, similar to that with an 
ATPase-inactive VCP or after proteasome inhibition (Dalal et al., 
2004). Finally, the clearance of an aggregated polyglutamine 
is slowed in IBMPFD mutant cells (Ju et al., 2008). This was 
caused by impaired protein aggregate trafficking to an aggre-
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they become autolysosomes. One way to distinguish an auto-
phagosome from an autolysosome is to use a tandemly tagged 
monomeric RFP (mRFP)–GFP-LC3 reporter (tfLC3; Kimura 
et al., 2007). This reporter fluoresces green and red in the neu-
tral environment of the autophagosome, distinguishing it from 
the acidic environment of an autolysosome which quenches the 
green fluorescence, leaving only the red fluorescence detectable. 
We transfected control, Scr control, VCP-KD, or cells express-
ing VCP-WT, -EQ, -RH, or -AE with the tfLC3 reporter. As a 
positive control, cells were treated with Baf to inhibit autolyso-
some formation. To induce autophagosome maturation, cells 
were incubated with rapamycin for 2 h, a time point determined 
to be optimal for the visualization of autolysosomes. Rapamy-
cin is capable of inducing autophagy in U20S cells, as measured 
by GFP-LC3–positive puncta and the conversion of LC3I to 
LC3II (unpublished data). Control, Scr control, and VCP-WT–
expressing cells had fewer green/red autophagosomes and more 
red autolysosomes than cells cotreated with Baf for 2 h (Fig. 3, 
A and B). The correlation coefficient of red dots to green dots 
was calculated for control cells as Y0.5, whereas this measure 
was Y0.8 in Baf-treated cells (Fig. 3 C). Similar to the Baf-treated 
cells, VCP-KD and -EQ and both IBMPFD mutants had an in-
crease in red/green-positive structures and a colocalization coef-
ficient of >0.75 (Fig. 3, A and C). To confirm that autolysosome 
(VCP-EQ) or one of two IBMPFD mutants, VCP-RH or VCP-
A232E (VCP-AE), at approximately two to three times the 
endogenous VCP (Ju et al., 2008). Immunoblots for LC3 or p62 
from cell lysates of 16 h–induced U20S cells identified an in-
crease in p62 and the LC3II fragment of LC3 in IBMPFD 
mutant (RH and AE)– and VCP-EQ–expressing cells (Fig. 2 C). 
Lentiviral transfection of the parental U20S cell line with 
VCP-WT–, VCP-EQ–, or IBMPFD mutant–expressing constructs 
gave identical results, suggesting that our finding was not caused 
by the clonal nature of the U20S stable cells (unpublished data). 
Just as with VCP-KD, there was an increase in basal GFP-LC3 
puncta in VCP-EQ or IBMPFD mutant cells when compared with 
control or VCP-WT cells (Fig. 2, D and E). The increase in GFP-
LC3 puncta was similar to that seen when VCP-WT or control 
cells were treated with bafilomycin A (Baf), an inhibitor of au-
tophagosome–lysosome fusion and lysosomal vacuolar-type H+-
ATPase, for 4 h (Fig. 2, D and E). Interestingly, VCP-EQ– and 
IBMPFD mutant–expressing cells did not significantly increase 
the number of GFP-LC3–positive puncta upon treatment with 
Baf for 4 h (Fig. 2 E). These data suggest that loss of VCP activity 
or IBMPFD mutant VCP expression does not disrupt autophago-
some formation and results in their accumulation.
Normally, an autophagosome acquires acidic properties 
after fusion with organelles such as lysosomes. Once fused, 
Figure 1. LC3 and p62 accumulate in IBMPFD muscle 
tissue. (A and B) Immunoblot of 9-mo-old quadriceps 
muscle lysates from control (cont) or VCP-WT, -RH9, or 
-RH12 mutant transgenic lines with p62 (A) or LC3 (B) 
antibodies. Note the increase in p62 and LC3II isoforms 
in mutant animals. Densitometric quantiﬁcation is from 
more than six 9-mo-old animals/group. LC3 and p62 
levels are normalized to loading control. Error bars 
represent the standard error from six independent 
experiments. **, P < 0.001. AU, arbitrary unit. (C) p62 
immunostaining of tibialis anterior (TA) or quadriceps 
(Quad) muscle from 9-mo-old control, VCP-WT, or one 
of two VCP-RH transgenic lines (RH9 or RH12). Note 
accumulations of p62 in the middle of myoﬁbers or 
along subsarcolemmal regions. (D) Histochemistry and 
immunohistochemistry of quadriceps muscle from VCP-
RH–expressing transgenic mice. Hematoxylin and eosin 
(H&E) staining of a 15-mo-old animal with an RV, p62 
immunostaining of an RV from a 12-mo-old animal, LC3 
immunostaining of an RV, and subsarcolemmal accu-
mulations of LC3 from a 12-mo-old animal. The bracket 
highlights one LC3-positive myoﬁber. A single muscle 
ﬁber is outlined in white. (C and D) Arrows denote vacu-
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Figure 2. LC3 and p62 accumulate in VCP-KD and IBMPFD mutant–expressing cells. (A) Lysates from scrambled siRNA or VCP-targeted siRNA–treated 
U20S cells immunoblotted with antibodies to VCP, LC3, p62, or A-tubulin. Densitometric analysis is graphically represented from four independent experi-
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increased with Baf, whereas both IBMPFD mutant–expressing 
cells did not increase LC3II protein levels further (Fig. 3 D). 
These data are consistent with the results in Fig. 2 (D and E), 
in which Baf treatment failed to increase the amount of 
GFP-LC3–positive puncta further than that already seen under 
basal conditions. These data suggest that loss of VCP function or 
formation was impaired, we immunoblotted lysates from cells 
expressing VCP-WT or mutant VCP with and without Baf for 
4 h. In normal cells, Baf increases the levels of LC3II protein, 
whereas in cells with a defect in autophagosome–lysosome fu-
sion, it will not increase LC3II levels (Rubinsztein et al., 2009). 
The LC3II species in control and VCP-WT–expressing cells 
KD cells expressing GFP-LC3. Basal numbers of GFP-LC3 puncta/cell were counted. (C) Lysates from control or myc-tagged VCP-WT, ATPase-inactive VCP-EQ, or 
one of two IBMPFD mutants, VCP-RH or -AE, expressed for 16 h from stably transfected tetracycline-inducible U20S cells and immunoblotted with antibodies 
to myc, LC3, p62, or A-tubulin. Densitometric analysis is graphically represented from four independent experiments. LC3 and p62 levels are normalized to 
loading control. Note the increase in LC3II and p62 in VCP siRNA KD and mutant-expressing cells. (D) Fluorescent microscopy images of tetracycline-inducible 
U20S cells expressing GFP-LC3 treated with and without Baf for 4 h (DMSO control [left] or Baf+ [right]). Cells are control U20S cells and VCP-WT, -RH, 
-AE, and -EQ. (E) The number of GFP-LC3 puncta/cell was counted for control U20S and VCP-WT, -EQ, -RH, and -AE with and without Baf for 4 h (DMSO 
or Baf). Note the increase in basal GFP-LC3 puncta in mutant-expressing cells. (A–C and E) Error bars represent the standard error from four independent 
experiments.*, P < 0.01; and **, P < 0.001. Bars, 25 μm.
 
Figure 3. Functional VCP is required for autophagosome maturation. (A) Epiﬂuorescent images for GFP and mRFP in U20S or VCP-WT–, VCP-RH–, 
VCP-AE–, or VCP-EQ–expressing cells transfected with mRFP-GFP-LC3 (tfLC3) and treated with rapamycin for 2 h to induce autolysosome formation. 
(B) siRNA control (Scr) or VCP-KD– or Baf-treated control U20S cells transfected with tfLC3 and treated with rapamycin for 2 h to induce autolysosome formation. 
(A and B) Open arrows denote autophagosomes (both GFP and mRFP ﬂuorescence), whereas closed arrows highlight autolysosomes (mRFP only ﬂuores-
cence). (C) The graph represents Pearson’s coefﬁcient of GFP and mRFP colocalization from 10 independent ﬁelds of cells in two different experiments. Error 
bars represent the standard error from 20 ﬁelds in two independent experiments. *, P < 0.001. (D) Lysates from U20S or tetracycline-inducible VCP-WT, 
-RH, or -AE cells treated with vehicle or Baf for 4 h and immunoblotted for LC3 and A-tubulin. Note that Baf treatment does not increase the LC3II levels in 
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therefore not be seen under our assay conditions (for review 
see Klionsky et al., 2008). In contrast, VCP-KD–treated cells 
failed to degrade LC3II (Fig. 4 A). A similar experiment was 
performed using control, VCP-WT and -EQ, and IBMPFD 
mutant cells. For these experiments, endogenous LC3II was 
detected after immunoblot of cell lysates after nutrient depri-
vation for up to 6 h. Although control or VCP-WT cells had a 
decrease in LC3II, VCP-EQ and IBMPFD mutant VCP cells 
failed to degrade LC3II as rapidly (Fig. 4 B). This is shown 
graphically after densitometric analysis from three indepen-
dent experiments (Fig. 4 C).
Next, we evaluated the colocalization of GFP-LC3 puncta 
with endosomal/lysosomal markers, LysoTracker red (LTR), 
or endogenous Lamp1 after a 2-h treatment with rapamycin to 
see whether autophagosome–lysosome fusion is defective. 
Control or VCP-WT cells had GFP-LC3 puncta that colocal-
ized or were adjacent to LTR (Fig. 5 A)- or Lamp1 (Fig. 5 C)-
positive vesicles, with a colocalization coefficient of Y0.5 
(Fig. 5, B and D). In VCP-EQ, IBMPFD mutant VCP, or con-
trol cells cotreated with Baf, there was a decrease in the co-
localization of GFP-LC3 puncta and LTR (Fig. 5 A) or Lamp1 
(Fig. 5 C), with a colocalization coefficient of Y0.3–0.4 (Fig. 5, 
B and D). Similar results were obtained using coexpression of 
an mRFP-LAMP1 fusion protein (unpublished data). To dem-
onstrate that GFP-LC3–positive structures were consistent 
with accumulating autophagosomes, we used electron micros-
copy. Vacuolated structures consistent with autophagosomes 
and lysosomes were identified in VCP-RH– and VCP-AE– 
expressing cells (Fig. 5 E). These data suggest that IBMPFD 
mutant VCP may lead to dysfunctional fusion of autophago-
somes with lysosomes.
We reasoned that RVs may be similar accumulations of 
nondegradative autophagosomes seen in cell culture. Immuno-
histochemistry of quadriceps muscle with p62 and Lamp1 re-
vealed deposition in 9-mo-old VCP-RH mouse muscle within 
the central region of myofibers and around RV-like structures in 
some fibers that was not apparent in VCP-WT or control ani-
mals (Fig. 6 A). This colocalization did not completely overlap, 
with some p62 puncta being distinct from Lamp1-positive 
puncta. A similar pattern was seen using IBMPFD patient mus-
cle in which a p62-positive RV contained Lamp2-positive 
vesicles (Fig. 6 A). Consistent with the accumulation of non-
degradative autophagosomes, RVs in IBMPFD- and VCP-RH–
expressing mice failed to label with hydrolytic enzyme stains 
such as acid phosphatase and nonspecific esterase (Fig. S3, 
C and D). Ultrastructural analysis identified structures contain-
ing accumulations of membranous vacuoles in VCP-RH muscle 
(Fig. 6, B and C).
To validate a functional consequence of impaired autophagy, 
we used a quantitative luciferase-based assay that measures selec-
tive protein aggregate degradation upon autophagic stimulation 
(Ju et al., 2009). This assay utilizes two luciferase reporters fused 
to a nonaggregating polyglutamine repeat (polyQ19-luciferase) or 
an aggregation-prone expanded polyglutamine repeat (polyQ80-
luciferase) electroporated into the left and right tibialis ante-
rior of 6-mo-old control or VCP-WT or -RH (RH9 and RH12) 
transgenic mice. Using in vivo bioluminescent imaging, baseline 
IBMPFD mutant VCP expression results in the accumulation of 
nondegradative autophagosomes.
We evaluated degradation of an autophagic substrate in 
VCP-inactive or IBMPFD mutant–expressing cells via an LC3 
immunoblot. The degradation of the autophagosome-associated 
LC3II fragment is a specific marker of autophagic flux in cells 
(for review see Klionsky et al., 2008). Either Scr control or 
VCP-KD cells had autophagy induced via nutrient deprivation 
and were harvested for immunoblotting at 0, 2, or 4 h. An 
immunoblot of Scr control cell lysates for LC3 demonstrates a 
decrease in LC3II protein over the 4 h (Fig. 4 A). We did not 
see a transient increase in LC3II levels indicative of a conver-
sion of LC3I to LC3II upon autophagic induction because the 
earliest time point evaluated was 2 h. Previous studies show 
that this conversion in cell culture occurs before 2 h and would 
Figure 4. Functional VCP is required for autophagic protein degradation. 
(A) Lysates from siRNA-treated U20S cells (scramble control [Scr] or VCP 
siRNA KD) after autophagic induction via nutrient deprivation for 0, 2, or 
4 h and immunoblotting for LC3 and A-tubulin. LC3II degrades over time 
in control but not in KD cells. One of two experiments is shown. (B) Lysates 
from U20S or tetracycline-inducible VCP-WT, -EQ, -RH, or -AE cells after 
autophagic induction via nutrient deprivation for 0, 2, 4, or 6 h and 
immunoblotting for LC3 and A-tubulin. LC3II degrades in control and VCP-WT 
but degrades less efﬁciently in mutant (EQ, RH, or AE)-expressing cells. 
(C) Graphical representation of densitometric evaluation of LC3II and 
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(Fig. 7 A). The change in the ratio of polyQ80-luciferase/
polyQ19-luciferase was calculated for three animals/treatment 
condition. Control and VCP-WT animals had a mean decrease in 
measurements of luciferase activity were taken 2 d after elec-
troporation (Fig. 7 A). Animals were then starved for 24 h, 
and repeat luciferase activity measurements were recorded 
Figure 5. Autophagosomes have decreased localization with lysosomal markers in IBMPFD mutant–expressing cells. (A) Epiﬂuorescent images for GFP-
LC3 (LC3) and LTR of VCP-WT–, VCP-RH–, VCP-AE–, or VCP-EQ–expressing cells transfected with GFP-LC3 and treated with rapamycin for 2 h to in-
duce autolysosome formation. Open arrows highlight autolysosomes (GFP and LTR colocalized), and closed arrows show autophagosomes (GFP only). 
(B) Pearson’s coefﬁcient of GFP and LTR colocalization from 10 independent ﬁelds of cells in two different experiments. (C) Epiﬂuorescent images for GFP-LC3 
and endogenous Lamp1 immunohistochemistry of U20S, VCP-WT–, VCP-RH–, VCP-AE–, or VCP-EQ–expressing cells or U20S cells cotreated with Baf trans-
fected with GFP-LC3 and treated with rapamycin for 2 h to induce autolysosome formation. Arrows highlight autolysosomes (GFP and Lamp1 colocalized). 
(A and C) The boxed regions in the merge ﬁeld are enlarged in the adjacent panels. (D) Pearson’s coefﬁcient of GFP and Lamp1 colocalization from 10 
independent ﬁelds of cells in two different experiments. (B and D) Error bars represent the standard error from 20 ﬁelds in two independent experiments. 
*, P < 0.001. (E) Electron microscopy of tetracycline-inducible control or VCP-WT–, VCP-RH–, or VCP-AE–expressing U20S cells induced for 16 h and then 
treated with rapamycin for 2 h. Note the accumulation of autophagic structures in the mutant-expressing cell lines. Arrows denote autophagic structures. 
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control U20S cells with agents known to impair autophagosome 
maturation such as chloroquine and Baf for 4 h resulted in the 
cytosolic accumulation of transfected TDP-43 (Fig. 8, A and B). 
Lysates from similarly transfected cells were separated into 
nuclear and cytosolic fractions. These fractions were immuno-
blotted for mCherry–TDP-43 along with lamin A/C and actin to 
confirm similar protein loading and the integrity of the frac-
tions. mCherry–TDP-43 was enriched in IBMPFD mutant– and 
VCP-EQ–expressing cell cytoplasm when compared with 
VCP-WT–expressing cells (Fig. 8 C). There was no clear differ-
ence in the amount of nuclear TDP-43 in these same cells. These 
data were similar to that seen when cell fractionation was per-
formed on lysates from U20S cells treated with chloroquine or Baf 
for 4 h (Fig. 8 C) and suggests that a block in autophagosome mat-
uration can increase the amount of cytosolic TDP-43.
polyQ80-luciferase/polyQ19-luciferase of Y25% and 18%, re-
spectively (Fig. 7 B). In contrast, RH12 and RH9 transgenic 
lines had an increase in the ratio of polyQ80-luciferase/polyQ19-
luciferase. These data suggest that VCP-RH animals have a defect 
in the autophagic clearance of protein aggregates.
One feature of IBMPFD is the loss of nuclear TDP-43 and 
accumulation cytoplasmic TDP-43 inclusions (Neumann et al., 
2007; Weihl et al., 2008). To see whether TDP-43 accumulated 
in the cytoplasm of IBMPFD mutant–expressing cells, we trans-
fected a human TDP-43 with an N-terminal mCherry tag 
(mCherry–TDP-43) into our tetracycline-inducible U20S cells. 
After 48 h of mCherry–TDP-43 expression, we quantitated the 
percentage of mCherry-positive cells having nuclear only or 
cytosolic fluorescence (Fig. 8 A). Because TDP-43 leaves the 
nucleus during cell division and cell death (unpublished data), 
we costained with DAPI to visualize mitotic figures and pyk-
notic nuclei. This allowed us to only count cells with intact nu-
clei. Similar to a previously reported study, IBMPFD mutant– and 
VCP-EQ–expressing cells had an increase in cytosolic TDP-43 
(Fig. 8, A and B; Gitcho et al., 2009). Similarly, treatment of 
Figure 6. Autophagic and lysosomal markers localize to RVs in IBMPFD 
tissue. (A) Immunoﬂuorescence images of quadriceps muscle using p62 
and Lamp1 or -2 antibodies. Quadriceps section from a 9-mo-old VCP-WT 
mouse, age-matched VCP-RH transgenic, 12-mo-old VCP-RH transgenic, 
and IBMPFD patient muscle biopsy are shown. Open arrows highlight p62 
and Lamp1/2 colocalization, and closed arrows show regions of only 
p62 immunoﬂuorescence. Single myoﬁbers containing RVs are outlined in 
the merge panels. (B and C) Transmission electron microscopy of tibialis 
anterior muscle from one of two independent lines (B shows RH12, and 
C shows RH9 lines) of 12-mo-old VCP-RH–expressing transgenic mice. 
Note the large vacuolated structures that are perinuclear or subsarcolemmal. 
Bars: (A) 30 μm; (B and C) 500 nm.
Figure 7. Impaired autophagic substrate degradation in IBMPFD mouse 
muscle. (A) Representative images using in vivo bioluminescence of control 
or IBMPFD mutant RH–expressing mice (RH12) 2 d after electroporation 
(baseline) or after 24 h of nutrient deprivation (starvation) of polyQ80 
(Q80)- or polyQ19-luciferase (Q19) in the right and left tibialis anterior, re-
spectively. The ratio of polyQ80-luciferase/polyQ19-luciferase is indicated 
below each image set. Values are in ×104 photons per second per square 
centimeter per steradian. (B) Box and whisker plot of the change ($) in the 
ratio of polyQ80-luciferase/polyQ19-luciferase activity in the left and right 
tibialis anterior muscle of control, VCP-WT, or one of two VCP-RH (RH12 
or RH9) transgenic mouse lines after 24 h of starvation. The graph is repre-
sentative of three animals per group. The p-value for RH12 was 0.05 and 
0.06 when compared with control animals or VCP-WT transgenic. The 
p-value for RH9 was 0.03 when compared with either control or VCP-WT 
transgenic. The p-value was 0.01 and 0.02 when combined RH12 and 
RH9 animals were compared with control or VCP-WT groups, respectively. 
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for human skeletal muscle (Fig. 9 A; Weihl et al., 2008; 
Salajegheh et al., 2009). In contrast, skeletal muscle from simi-
larly aged RH9 and RH12 transgenic mice had a reduction of 
TDP-43 immunofluorescence within nuclei and an increase in 
perinuclear sarcoplasmic TDP-43 (Fig. 9 A). In some fibers, 
TDP-43 immunostaining was concentrated in small punctuate 
inclusions throughout the sarcoplasm or in central regions of 
the myofiber consistent with an RV (Fig. 9 A). This pattern is 
Next, we evaluated TDP-43 immunolocalization in con-
trol and VCP-WT– and IBMPFD mutant–expressing animals. 
Notably, fixation of skeletal muscle with acetone abolished 
all nuclear TDP-43, whereas fixation with PFA and then ace-
tone resulted in TDP-43 immunofluorescence in Y80–90% of 
nuclei from mouse skeletal muscle (Fig. S4). TDP-43 was pre-
dominantly within nuclei from 15-mo-old control and VCP-WT–
expressing animal muscle, similar to that previously reported 
Figure 8. IBMPFD mutant expression or autophagic inhibition redistributes TDP-43 to the cytosol in cells. (A) Quantitation of mCherry–TDP-43 distribution 
(nuclear only or cytoplasmic) in control U20S, VCP-WT–, VCP-RH–, VCP-AE–, or VCP-EQ–expressing cells, or control U20S cells treated with 10 μM Baf 
or 50 μM chloroquine (Chlq) for 4 h from 10 different ﬁelds from two independent experiments. Error bars represent the standard error from 20 ﬁelds in 
two independent experiments. *, P < 0.02 when compared with VCP-WT–expressing cells. (B) Epiﬂuorescent images for mCherry–TDP-43 (red) and DAPI 
(blue) in control U20S, VCP-WT–, VCP-RH–, or VCP-AE–expressing cells, or control U20S cells treated with Baf or chloroquine for 4 h. Arrows denote 
cytosolic TDP-43 and perinuclear TDP-43 inclusions. (C, top) Immunoblot for TDP-43, lamin A/C, and actin from nuclear or cytosolic lysate fractions of 
mCherry–TDP-43–transfected VCP-WT–, VCP-RH–, VCP-AE–, or VCP-EQ–expressing cells. Note the increase in cytosolic TDP-43 from IBMPFD mutant– and 
EQ-expressing cells. (bottom) Immunoblot for TDP-43, lamin A/C, and actin from nuclear or cytosolic lysate fractions of untreated U20S cells transfected 
with mCherry–TDP-43 or similarly transfected cells treated with 30 μg/ml (cq1) or 120 μg/ml (cq2) chloroquine diphosphate or 200 ng/ml Baf. Data are 
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Discussion
We demonstrate that loss of VCP activity impairs autophagy. 
Specifically, LC3-positive vacuoles fail to mature into auto-
lysosomes, resulting in the accumulation of nondegradative 
autophagosomes. Moreover, measures of autophagic flux are 
impaired in cells lacking a functional VCP. Expression of the 
IBMPFD mutant VCP-RH or -AE leads to similar results with 
dysfunctional autophagosomes accumulating at RVs in IBMPFD 
patient and transgenic mouse muscle. TDP-43 accumulation 
in the cytosol occurs in IBMPFD mutant–expressing cells and 
animals as well as with chemical inhibition of autophagosome 
maturation in vitro and in vivo. Our data suggest that IBMPFD 
is a disorder of autophagosome maturation resulting in dysfunc-
tional autophagy.
A defect in autophagosome maturation explains many of 
the pathological features seen in IBMPFD muscle. For example, 
ubiquitinated aggregates and p62 inclusions are present in 
autophagy-deficient tissue (Hara et al., 2006; Komatsu et al., 
2007). RVs, which are speculated to be of autophagic origin, are 
indeed accumulations of p62- and LC3-positive autophago-
somes in IBMPFD. Autophagic inhibition via pharmacologic 
treatment with chloroquine, which is an inhibitor of lysosomal 
proteases, in mice or patients results in a myopathy with vacu-
oles and protein accumulation (Suzuki et al., 2002). Similarly, 
toxic administration of the microtubule-disrupting drugs colchi-
cine and vinblastine results in a myopathy with RVs (Kuncl 
et al., 2003). The mechanism of action with these drugs is pro-
posed to be a defect in autophagosome/lysosome trafficking.
The role of autophagy in skeletal muscle is unclear. Skel-
etal muscle–specific knockout of the autophagy essential pro-
tein ATG5 in mice leads to type II muscle fiber atrophy with an 
accumulation of ubiquitin and p62 within these fibers (Raben 
et al., 2008). In contrast, skeletal muscle atrophy induced by 
constitutively active FOXO3 (forkhead box O3) was reduced 
when muscle was treated with silencing RNAs directed to LC3 
(Mammucari et al., 2007). Impairment in autophagosomal–
lysosomal degradation is the proposed mechanism in other vacu-
olar myopathies such as Danon’s disease (Nishino et al., 2000) 
and X-linked myopathy with excessive autophagy (Ramachandran 
et al., 2009). These myopathies, similar to IBMPFD, accumu-
late undegraded protein in association with membranous struc-
tures. Presumably, mice deficient in skeletal muscle autophagy 
genes such as ATG5 do not make autophagosomes, whereas in 
the case of IBMPFD, autophagosomes are formed yet fail to 
mature and be degraded. Perhaps the cytoskeletal derange-
ments and membranous accumulations that occur in vacuolar 
myopathies are deleterious to skeletal muscle function and ex-
plain the pathological disconnect between autophagy-deficient 
and -defective muscle.
TDP-43 redistribution from the nucleus to the cytosol 
and subsequent aggregation is a feature seen in IBMPFD 
patient muscle (Weihl et al., 2008). Sarcoplasmic TDP-43 colo-
calizes with ubiquitin, suggesting that its degradation is affected 
(Weihl et al., 2008). This feature is seen in other muscle dis-
orders with RVs, including sIBM and hIBM2 (Weihl et al., 2008; 
Küsters et al., 2009; Salajegheh et al., 2009). The cause of RVs 
identical to that seen in IBMPFD patient skeletal muscle (Fig. S3, 
M and N) and never seen in control, VCP-WT–expressing 
mice, or normal patients. Rodents chronically administered 
chloroquine develop an RV myopathy with LC3- and acid 
phosphatase–positive vacuoles presumably caused by the im-
paired lysosomal degradation of autophagic components (Ikezoe 
et al., 2009). We evaluated the localization of TDP-43 in 3-mo-old 
mice treated with 50 mg/kg chloroquine per day for 1 mo com-
pared with age-matched control mice treated with daily injec-
tions of buffered saline. Consistent with a previous study 
(Ikezoe et al., 2009), chloroquine treatment caused vacuolation, 
myofiber degeneration, and the accumulation of p62 and LC3II 
(Figs. S1 and S4). TDP-43 immunostaining in chloroquine-treated 
animals was similar to that seen in IBMPFD mutant–expressing 
animals and patients. Specifically, myofibers accumulated 
TDP-43 in the sarcoplasm adjacent to nuclei from chloroquine-
treated animals (Fig. 9 B). These data suggest that a block in 
autophagic protein degradation recapitulates TDP-43 pathol-
ogy in IBMPFD.
Figure 9. IBMPFD mutant expression or autophagic inhibition redistributes 
TDP-43 to the cytosol in mouse skeletal muscle. (A) TDP-43 immunostaining 
of quadriceps skeletal muscle from 15-mo-old control (Cont) or VCP-WT, 
-RH9, or -RH12 transgenic mice. A single myoﬁber is outlined in white. 
(B) TDP-43 immunostaining of quadriceps skeletal muscle from 3-mo-old mice 
treated with saline or 50 mg/kg/d intraperitoneal chloroquine (Chlq) for 
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This study does not preclude the possibility that the UPS 
or the degradation of muscle-specific UPS substrates is im-
paired in IBMPFD. We previously reported that steady-state 
levels of $F508CFTR are increased in IBMPFD mutant VCP 
myoblasts (Weihl et al., 2006). We suggested that this was 
caused by a defect in UPS-mediated degradation. However, our 
current data open the possibility that $F508CFTR accumulates 
because of IBMPFD mutant’s effect on autophagy. Whether this 
is via direct degradation of the ERAD substrate by autophagy 
or a secondary impairment in the UPS as seen with chronic 
autophagic inhibition is not known (Korolchuk et al., 2009). 
Regardless, it is conceivable that previous studies evaluating 
the degradation of UPS substrates and accumulation of ubiqui-
tinated proteins reflect a primary defect in autophagy mediated 
by IBMPFD mutants rather than dysfunctional UPS (Weihl 
et al., 2006; Janiesch et al., 2007; Ju et al., 2008).
The mechanism by which VCP regulates autophagy remains 
to be elucidated. Our data suggest that loss of VCP does not affect 
the induction of autophagy but instead impairs autophagosome 
maturation to acidic autolysosomes. This can be caused by de-
fects in autophagosome/lysosome trafficking or autophagosome–
lysosome fusion. We have previously shown that IBMPFD 
mutations in VCP affect the trafficking of protein aggregates to an 
inclusion body (Ju et al., 2008). This leads to impaired autopha-
gic degradation of aggregated polyglutamine-containing protein. 
Whether IBMPFD mutants could also affect the trafficking of 
autophagosomes to inclusion bodies is not known but would be 
consistent with our current data. VCP performs its functions via 
interactions with ubiquitinated intermediates or by association 
with ubiquitin-like domains (Schuberth and Buchberger, 2008). 
These cofactors contain a homologous 76–80-aa sequence 
with structural similarities to ubiquitin. Several autophagosome-
associated proteins (LC3, GABARAP, and GATE-16) also have 
domains with homology to ubiquitin (Sou et al., 2006). Whether 
VCP forms a complex with these proteins to mediate autopha-
gosome–lysosome fusion is speculative. However, another AAA+ 
protein, NSF, associates with GATE-16 (Sagiv et al., 2000). NSF 
mediates the assembly of GATE-16 and GOS-28, a Golgi 
v-SNARE required for homotypic membrane fusion (Muller 
et al., 2002). Our study identifies an essential role for VCP in 
autophagy and implicates dysfunctional autophagy in the patho-
genesis of IBMPFD, its phenotypic variants (IBM, PDB, and 
FTLD-U), and perhaps other TDP-43 proteinopathies.
Materials and methods
Plasmids and cell culture
PolyQ19- and polyQ80-luciferase constructs were previously described 
(Ju et al., 2009). LC3-GFP plasmid and tfLC3 tandemly tagged with GFP and 
mRFP construct were obtained from the laboratory of H. Virgin (Washing-
ton University, St. Louis, MO). mCherry–TDP-43 was constructed as fol-
lows: a cDNA encoding human full-length TDP-43 with an N-terminal Flag 
tag was generated by PCR using the full-length human TDP-43 cDNA 
(Thermo Fisher Scientiﬁc) as a template. The Flag sequence was placed im-
mediately after the start methionine, with the ﬁnal sequence MDYKDDDK-
SEYIR. This PCR product was cloned into the XhoI and BamHI sites in frame 
with the mCherry red ﬂuorescent protein in the vector pCherry-C1, which 
was generated by replacing EGFP with mCherry on the pEGFP-C1 back-
bone. U20S TRex stable cell lines (VCP-WT, -EQ, -RH, and -AE point muta-
tions) were established and cultured as described previously (Ju et al., 2008). 
in these disorders is not known but has been presumed to be 
secondary to autophagy. We demonstrate that TDP-43 accumu-
lates in the cytoplasm of IBMPFD mutant–expressing cells and 
transgenic mouse muscle. This pathological finding is recapit-
ulated under conditions of impaired autophagosome–lysosome 
fusion after chloroquine and Baf treatment. We suggest that 
IBMPFD mutants disrupt autophagy and that this subsequently 
leads to the accumulation of cytosolic TDP-43. One recent 
study found that VCP and TDP-43 could interact in cell culture 
and patient tissue (Gitcho et al., 2009). They proposed that 
TDP-43 may be a substrate for VCP. It has been speculated that 
TDP-43 or its fragments may be degraded via autophagy and 
accumulate when autophagy is dysfunctional (Filimonenko 
et al., 2007; Caccamo et al., 2009; Kadokura et al., 2009; Kim 
et al., 2009). How TDP-43 redistribution affects skeletal mus-
cle and whether TDP-43 or its fragments are bona fide autoph-
agy substrates remain to be determined.
This study focuses principally on the skeletal muscle 
pathogenesis of IBMPFD. Muscle weakness is the presenting 
feature in >50% of IBMPFD patients, and 90% of IBMPFD pa-
tients develop IBM with significantly less phenotypically ex-
pressing PDB and FTD (Y51% and Y32%, respectively; Weihl 
et al., 2009). Moreover, the pathologies in IBMPFD patient 
muscle and neurons are distinctively different. For example, 
IBMPFD brain tissue has predominantly nuclear ubiquitinated 
inclusions with rare cytoplasmic inclusions (Schröder et al., 
2005; Forman et al., 2006), whereas IBMPFD skeletal muscle 
tissue has ubiquitin-positive nuclei and abundant sarcoplasmic 
ubiquitinated inclusions (Hübbers et al., 2007; Gidaro et al., 
2008; Weihl et al., 2009). Similarly, IBMPFD brain tissue has 
nuclear TDP-43 inclusions as well as a reduction of TDP-43 
from the nuclei of affected cortical neurons (Neumann et al., 
2007), whereas IBMPFD skeletal muscle has the exclusive 
accumulation of sarcoplasmic TDP-43 and absence from the 
myonuclei of inclusion-bearing myofibers (Weihl et al., 2008; 
Küsters et al., 2009; Salajegheh et al., 2009). The reason for 
these pathological differences is unknown but may relate to how 
muscle and brain tissue handle autophagic insults.
A disruption in autophagy is consistent with data from 
other diseases that share phenotypic features with IBMPFD 
(i.e., PDB and FTLD-U). Mutations in the autophagosome pro-
tein p62 cause PDB (Laurin et al., 2002). p62 binds ubiqui-
tinated proteins and LC3 (Pankiv et al., 2007). Under conditions 
of impaired autophagy, p62 mediates the aggregation of ubiqui-
tinated proteins (Komatsu et al., 2007) and sequesters them 
from the UPS (Korolchuk et al., 2009). Interestingly, VCP 
improves UPS function in the setting of p62 overexpression, 
identifying a potential point of intersection between the UPS 
and autophagy (Korolchuk et al., 2009). Mutations in CHMP2B 
(charged multivesicular body protein 2B) cause FTLD-U 
(Skibinski et al., 2005). CHMP2B is a member of the ESCRT 
(endosomal-sorting complex required for transport) pathway, 
which facilitates the endosomal/lysosomal degradation of plasma 
membrane proteins (Skibinski et al., 2005). ESCRT family mem-
bers, including CHMP2B, participate in autophagosome–lysosome 
fusion, and loss of ESCRTI and ESCRTIII family members leads 
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2.5% glutaraldehyde in Na cacodylate, embedded, sectioned, and stained 
with uranyl acetate according to standard procedures.
Western blotting
Muscle tissues and U20S culture cells were homogenized in ice-cold radio-
immunoprecipitation assay lysis buffer with protease inhibitor cocktail 
(Sigma-Aldrich), and lysates were centrifuged at 14,000 g for 10 min. Solu-
ble proteins were quantitated using a BCA protein assay kit (Thermo Fisher 
Scientiﬁc). Aliquots of homogenate were further solubilized in Laemmli sam-
ple buffer, and 20–50 μg of protein was subjected to SDS-PAGE (10–12% 
resolving gel). Proteins were transferred to nitrocellulose membranes (Trans-
Blot; 0.2-μm nitrocellulose; Bio-Rad Laboratories). Membranes were blocked 
in a solution of Tris-buffered saline containing 5% nonfat dry milk. The follow-
ing antibodies were used: anti-p97 (1:2,000), anti-Lamp1, and anti–lamin 
A/C (1:2,000; BD); anti-LC3 (1:2,000); anti-p62 (1:4,000), anti-GFP, and 
antiactin (Sigma-Aldrich); anti-myc and antitubulin (Cell Signaling Technol-
ogy); and anti–TDP-43 (1:2,000; N terminus; Proteintech). After incubation 
with the appropriate secondary antibody (horseradish peroxidase–conjugated 
IgG), bands were visualized by ECL. Immunoblots were scanned with a ﬁlm 
scanner (Perfection 1359; Epson), and images were collected in Photoshop 
CS3. Densitometry was measured with ImageJ.
Nuclear cytoplasmic fractionation
Cells were plated in 10-cm dishes. 8 h after transfection, tetracycline in-
duction was performed, and cells were grown for an additional 36 h. For 
autophagy inhibition experiments, transfected U20S cells were grown for 
24 h and then treated with the indicated concentrations of chloroquine, 
Baf, or vehicle alone for 6 h before. After treatment, cells were washed 
twice, scraped in cold PBS, and collected by centrifugation at 700 g for 
10 min. The cell pellet was resuspended in 400 μl of buffer A (10 mM, 
Hepes-KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT) sup-
plemented with 0.1 mM PMSF and a protease inhibitor cocktail (Sigma-
Aldrich), and the cells were allowed to swell on ice for 30 min and then 
vortexed for 10 s and passed seven times through a 29-gauge needle. 
Samples were centrifuged at 700 g for 10 min to pellet nuclei, and the 
postnuclear supernatant was collected in a new tube. To prevent carry-
over, the nuclear pellet was washed once in buffer A, and the postnuclear 
supernatant was additionally centrifuged at top speed for 10 s to remove 
all light debris and nuclei. To obtain the soluble cytosolic fraction, the 
postnuclear supernatant was centrifuged at 100,000 g for 1 h, and the 
soluble cytosolic fraction was concentrated by acetone precipitation. The 
cytosolic fraction was then resuspended in buffer B (20 mM Hepes-KOH, 
pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 0.5 mM DTT) 
supplemented with 1 mM PMSF and a protease inhibitor cocktail. To ob-
tain the nuclear fraction, nuclear pellets were resuspended in 50–70 μl of 
buffer B supplemented with 1 mM PMSF and a protease inhibitor cocktail 
and incubated on ice for 20 min for high salt extraction. The nuclear frac-
tion was collected after top speed centrifugation in a new tube. Protein 
concentration on each fraction was determined by the Bradford assay 
(Bio-Rad Laboratories), and 2 μg of nuclear and 8 μg of cytosolic fractions 
were subjected to immunoblotting.
Luciferase assays
Autophagic protein degradation in vivo was measured using in vivo electro-
poration and bioluminescent imaging of mice, as described previously 
(Ju et al., 2009). In brief, mice were electroporated with polyQ19- and 
polyQ80-luciferase constructs into the left and right tibialis anterior skeletal 
muscle, respectively. After 2 d of recovery, mice were anesthetized (isoﬂu-
rane inhalation), injected with 150 μg/g D-luciferin, and imaged with a 
charge-coupled device camera (IVIS imaging system; Caliper) for pretreat-
ment. Regions of interest were deﬁned manually over the tibialis anterior 
muscles for determining total photon ﬂux (photons per second). The ratio of 
polyQ80-luciferase/polyQ19-luciferase activity was determined for each 
animal. Imaging was performed after 24 h of starvation, and the ratio of 
polyQ80-luciferase/polyQ19-luciferase activity was again determined for 
each animal. The $ of the ratio was plotted for comparative purposes.
Statistical analysis
Data were evaluated by the paired Student’s t test and/or analysis of vari-
ance followed by Fisher LSD post hoc comparisons at P < 0.05.
Online supplemental material
Fig. S1 shows p62 and LC3 immunoblot analysis of skeletal muscle lysates 
from chloroquine-treated animals. Fig. S2 shows p62 immunoblots from 
IBMPFD, sIBM, and control patient muscle. Fig. S3 shows histochemical and 
immunohistochemical analysis of IBMPFD patient skeletal muscle biopsies. 
The cells were maintained in DME supplemented with penicillin/strepto-
mycin, 10% fetal bovine serum, 50 μg/ml hygromycin B, and 65 μg/ml Zeo-
cin at 37°C with 5% CO2. The stable cell lines were seeded in appropriate 
plates and grown to Y80% conﬂuence on the day of transfection. Transfec-
tions were performed with Lipofectamine 2000 (Invitrogen) or, in the case of 
mCherry–TDP-43, with Fugene 6 (Roche) according to manufacturers’ proto-
col. For amino acid starvation, cells were extensively washed with HBSS and 
further incubated in HBSS for the indicated time periods. Rapamycin was 
used at a ﬁnal concentration of 10 μg/ml for the indicated times. Baf was 
used at a concentration of 200 ng/ml, and chloroquine diphosphate was 
used at a concentration of 120 μg/ml.
Transfection of siRNA oligonucleotides
KD of VCP was achieved by treatment of U20S cells with siRNA duplexes, 
corresponding to the VCP RNA sequence (QIAGEN) or nontargeting 
siRNA duplexes (QIAGEN). Cells were transfected according to manufac-
turer’s instructions (HiPerFect transfection reagent; QIAGEN). In brief, cells 
were seeded onto 6-well plates 1 d before transfection to reach 70% con-
ﬂuence in a DME containing 10% FBS without antibiotics. Targeting siRNA 
or negative control siRNA were mixed with HiPerFect transfection reagent 
in OptiMEM (Invitrogen) for 15 min at room temperature and then added 
to the culture medium with a ﬁnal concentration of 50 nM of either oligo-
nucleotide. Cells were incubated at 37°C for 48 h. Cells were retransfected 
with either siRNA duplex in an analogous manner. After 48 h of second 
transfection, protein expression was determined by Western blotting using 
an antibody for VCP, which revealed an Y60–70% reduction of VCP.
Fluorescence and electron microscopy
U20S cells grown on glass coverslips were transiently transfected with plas-
mid or siRNA constructs. For stably expressing cells, 1 μg/μl tetracycline 
was added the day after transfection. 24–48 h after transfection, cells 
were washed twice with PBS, ﬁxed with 3% PFA in PBS for 15 min, perme-
abilized with 0.1% Triton X-100 in PBS for 10 min, washed, blocked with 
3% goat serum for 1 h, and stained for ﬂuorescence microscopy. For 
skeletal muscle immunohistochemistry, isolated skeletal muscle was 
mounted using tragacanth gum and quick frozen in liquid nitrogen–cooled 
2-methylbutane. Frozen biopsy samples were sectioned into 8-μM thick 
sections and ﬁxed in ice-cold acetone or 4% PFA and then acetone in the 
case of TDP-43 immunostaining (Fig. S5). Specimens were examined using 
a ﬂuorescent microscope (80i upright; Nikon) and charge-coupled device 
camera (EZ monochrome; Roper Industries) with deconvolution software 
analysis (NIS Elements; Nikon). Nonﬂuorescent images were taken with a 
5-megapixel color charge-coupled device (Nikon). Image processing and 
analysis were performed with NIS Elements 4.0 software and Photoshop 
CS3 (Adobe). All images were performed on ﬁxed cells or tissue at room 
temperature using Prolong Gold mounting solution (Invitrogen). Objectives 
used for immunoﬂuorescence were Apochromat 20× and 40×. Conju-
gated secondary antibody ﬂuorophores used were Alexa Fluor 488 and 
543 (Invitrogen). For colocalization analysis, 10 random ﬁelds of cells 
were selected, each containing at least two transfected cells. The Pearson’s 
colocalization coefﬁcient was determined for each cell using NIS Elements 
4.0 software. Results are from two independent experiments. LC3 puncta 
were calculated from four independent experiments in which ﬁve to eight 
low power ﬁelds were counted. All images were taken at the same gain 
and exposure intensity. Images were postprocessed using ImageJ software 
(National Institutes of Health) and the TOPHAT ﬁlter (http://u759.curie 
.u-psud.fr/softwaresu759.html) before the counting of dot intensity.
For mCherry–TDP-43 quantitation, U20S cells were seeded at 
50,000 cells per 12-well coverslips in antibiotic-free media and transfected 
on the next day. After transfection, cells were induced or treated with the in-
dicated drugs. After treatment, the coverslips were washed with PBS three 
times, ﬁxed in 4% PBS/PFA for 20 min, washed again, and mounted in ﬂuor-
escence mounting medium that contained DAPI to visualize nuclei. Decon-
voluted images from 10 random ﬁelds, each one containing at least 10 
transfected cells, were acquired with a microscope (Eclipse 80i; Nikon) 
using an Apochromat 20× objective. Acquisition was performed at the 
same gain and exposure setting. Cells were visualized with the NIS Ele-
ments Advanced Research 3.0 software (Nikon) and categorized as nuclear 
only or cytoplasmic containing based on the presence of Cherry ﬂuores-
cence outside the boundaries of the nucleus. Only cells carrying healthy nu-
clei were considered for counting purposes, based on a homogeneous 
DAPI staining. Dividing cells were excluded from the current analysis.
For thin-section electron microscopy, transiently transfected cells 
were grown to 70% conﬂuence in a 100-mm dish for 36 h. For sample 
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